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patient’s anatomy and the target volumes to be irradiated, 
and further individualized after balancing possible benefits 
and risks that can be anticipated based on the outcome of 
treatment planning. Therefore, in agreement with the 
“Pareto principle”, it is advisable to choose one basic 
treatment technique for the department that is most 
appropriate for 80% of the cases and select out of different 
other treatment setups in a highly individualized manner for 
the remaining 20% for which the basic treatment setup might 
not be optimal. 
In the meantime, our knowledge about breast cancer and its’ 
treatment continues to increase, leading to changing 
attitudes towards the selection of the most appropriate 
target volumes which might either be smaller like partial 
breast irradiation for low risk patients or quite more 
extended like comprehensive locoregional irradiation 
including the internal mammary lymph nodes for patients 
with adverse risk factors. At the same time, dose prescription 
will follow the outcome of prospective clinical trials with 
hypofractionation with daily doses below 3 Gy already widely 
introduced in daily clinical practice and with higher daily 
doses or dose variation over the target volumes depending on 
the risk of recurrences being investigated. This can only go 
hand in hand with a continuing improvement of treatment 
delivery with a more homogeneous dose distribution overall 
and if indicated an intended dose variation like in the 
simultaneous integrated boost technique for high risk 
volumes. For all of this, an optimal interdisciplinary 
collaboration between researchers, radiation oncologists, 
medical physicists and radiation therapists is obviously 
indispensable. 
   
 
Teaching Lecture: Evaluating toxicity of new targeted 
drugs  
 
 
SP-0199   
Evaluating the toxicity of new targeted drugs in 
combination with radiotherapy 
A.M. Brade1 
1Princess Margaret Cancer Centre - University Health 
Network - University of Toronto, Radiation Medicine 
Program, Toronto, Canada  
   
The aim of this lecture is to provide the practicing radiation 
oncologist with an overview of radiotherapy practice in the 
era of molecularly targeted agents, focusing on issues of 
safety and toxicity when these modalities are delivered 
concurrently or in interdigitated fashion.  
As more targeted agents are approved for the treatment of 
metastatic cancers, the challenge of managing these 
combinations in the palliative and oligometastatic settings, 
where the use of standard low- and SBRT dose range 
prescriptions are employed, respectively, is becoming 
increasingly common.  An overview of available clinical data 
will be provided for classes of agents in common use, 
including inhibitors of the EGFR, VEGF and mTOR axes.  
Immunomodulatory agents and PARP inhibitors will also be 
discussed. 
Design of clinical trials to evaluate combinations of targeted 
agents with radiotherapy also presents unique challenges. 
Issues regarding endpoint selection and DLT definition will be 
explored using data and illustrative examples.  Alternative 
approaches of capturing toxicity data, e.g. from population 
databases will also be discussed. 
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Quality assurance and commissioning of brachytherapy 
treatment planning systems (TPS) comprise among other 
tasks verification of single and multiple source isodose 
distributions, applicator reconstruction, electronic data 
transfer, optimization software and dose volume histogram 
calculations. Comparison of TPS derived plans against a 
second TPS is valuable as is end-to-end dose measurements 
of plan delivery. While output by dose calculation engines 
based on the TG43 formalism is easy to verify, the task is 
more complex for the recently introduced model based dose 
calculations algorithms (MBDCA). The American Association of 
Physicists in Medicine (AAPM) has initiated a “Working Group 
on Model-Based Dose Calculation Algorithms in 
Brachytherapy” to derive and distribute well defined test 
plans and recommendations for commissioning MBDCAs.  This 
lecture will cover existing recommendations for 
commissioning radiotherapy and in particular brachytherapy 
TPS, provide practical examples of the process and an update 
on the ongoing work to derive and distribute test plans for 
commissioning MBDCAs.  
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Abstract not received. 
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Purpose: Radiation induced pulmonary toxicity after radical 
radiotherapy or chemoradiation is difficult to score in lung 
cancer patients because tumor progression and exacerbation 
of preexisting pulmonary co-morbidities may have similar 
clinical characteristics. This presentation discusses several 
aspects of pulmonary toxicity. 
A mild dry cough is common during the acute phase of lung 
irradiation. Radiation Pneumonitis (RP) is characterized by 
dyspnea, unproductive cough and occasionally mild fever, 
and typically presents between 1-6 months after treatment. 
Severe late lung complications, like pulmonary fibrosis, 
